Skip to content

Anesthetic Efficacy of %4Alexadricaine Versus %2 Mepicaine-L in Children

Anesthetic Efficacy of %4Alexadricaine Versus %2 Mepicaine-L for Infiltration Anesthesia in Extraction of Maxillary First Primary Molars in Children

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04477317
Enrollment
10
Registered
2020-07-20
Start date
2021-08-01
Completion date
2021-10-30
Last updated
2023-03-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Local Anesthesia

Brief summary

The aim of the present study is to evaluate and compare the anesthetic efficacy of Alexadricaine versus Mepecaine-L infiltration anesthesia in children during extraction of badly decayed or unrestorable maxillary first primary molars.

Detailed description

To our knowledge, no clinical trials in literature have been done to compare anesthetic efficacy of 4% Articaine versus 2% Mepivacaine in pain management during extraction of badly decayed upper first primary molars. Thus, the purpose of the present study was to fill this knowledge gap. This trial will be held on a new brand of 4% articaine made in Egypt called Alexadricaine anesthetic solution where no clinical trials have been conducted on it yet in literature.

Interventions

DRUG4% Articaine Hydrochloride with 1:100,000 Adrenaline

new Egyptian articane anesthetic solution.

DRUG2% Mepivacaine Hydrochloride with 1:20,000 Levonordefrin

Mepecaine-L is the brand name of the Egyptian 2% Mepivacaine. It is the most commonly used anesthetic solution in Egypt due to its availability and its lower cost.

Sponsors

Cairo University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
5 Years to 7 Years
Healthy volunteers
Yes

Inclusion criteria

* Medically fit (ASA I, II). * Mentally capable of communication. * Children aged 5-7 years, children older than 8 years old will not be included due to physiologic root resorption associated with shedding which may simplify the extraction procedure(25). * First maxillary primary molar needs extraction due to root caries beyond possible repair. * First dental visit. * Child must give assent prior to participation, as well as approved parental informed written consent.

Exclusion criteria

* Children with acute or sub-acute dento-alveolar abscess Children with history of prolonged bleeding, platelet disorders, Hyperthyroidism or hypersensitivity. * Patients who had taken analgesics or antibiotics in the 12-hrs preceding the injection.

Design outcomes

Primary

MeasureTime frameDescription
Intra-operative pain during extractionthrough study completion, an average of 1 yearmeasured by Visual Analogue Scale (VAS) and Sound Eye Motor (SEM) scale

Secondary

MeasureTime frameDescription
onset of anesthesiathrough study completion, an average of 1 yearmeasured in minutes using stopwatch
duration of anesthesiathrough study completion, an average of 1 yearmeasured in minutes using stopwatch

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026